A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.

An Open-Label Randomized Incomplete Block Four-Way Crossover Study To Evaluate The Dose Response Of PF-02413873 Tablets And PF-02413873 Suspension.

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00857571

Enrollment

Registered

2009-03-06

Start date

2009-04-30

Completion date

2009-05-31

Last updated

2018-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Dose Response Bioavailability Study

Brief summary

The study compares the plasma concentrations of PF-02413873 after administration of several doses as suspension and as tablets

Interventions

DRUG30 mg Suspension

Single oral dose of 30 mg of PF-02413873 suspension

DRUG150 mg Suspension

Single oral dose of 150 mg of PF-02413873 suspension

DRUG400 mg Suspension

Single oral dose of 400 mg of PF-02413873 suspension

DRUG5 mg Suspension

Single oral dose of 5 mg of PF-02413873 suspension

DRUG750 mg Suspension

Single oral dose of 750 mg of PF-02413873 suspension

DRUG150 mg Tablet

Single oral dose of 150 mg of PF-02413873 tablets

DRUG30 mg Tablet

Single oral dose of 30 mg of PF-02413873 tablets

DRUG400 mg Tablet

Single oral dose of 400 mg of PF-02413873 tablets

DRUG5 mg Tablet

Single oral dose of 5 mg of PF-02413873 tablets

DRUG750 mg Tablet

Single oral dose of 750 mg of PF-02413873 tablets

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

21 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy male and female volunteers. * Female volunteers have to be of non-childbearing potential

Exclusion criteria

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). * Any condition possibly affecting drug absorption (eg, gastrectomy). * A positive urine drug screen.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics: Cmax, AUCinf	June - July 2009

Secondary

Measure	Time frame
Tmax, Tlag, AUClast, AUCt, t½, Frel.	June-July 2009

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026